From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Upcoming Events

This month we will learn more about the opportunity to ‘listen’ for safety signals in social media from the Sanofi Digital team, as they share some of their advanced analytics and visualization regarding what is being said
In this month's Diagnostics Lab meeting, we will be hearing from two groups working to enable the flow of health information throughout numerous vendors, implementers, networks and governance frameworks. We’ll hear first fr

Past Events

The topic for this month's Therapeutics/Vaccines Lab Meeting is "Test to Treat."
This month's Diagnostics Lab meeting we will look at LAMP-based diagnostics; Testing in the airline industry and air travel. We will hear presentations from Dr.
Naloxone Access: Answering Questions Virtual Public Meeting  Tuesday, March 29, 2022
During this week's Therapeutics/Vaccines Lab meeting we will host an interview moderated by Duke University's Dr. Murali Doraiswamy. During the interview, Dr. Doraiswamy will speak with Dr.
This week's Diagnostics Lab Meeting will feature presentations focused on tying diagnostics and therapeutics, using patient-level variant testing to determine availability of certain monoclonal antibodies (mAbs).
The Accelerated Approval Pathway was created by Congress to allow patients with a serious or life-threatening disease earlier access to a potentially important treatment. At this virtual public meeting we explored the insights and lessons learned in the 30 years since its inception.
 02/17/2022 - 03:00 PM
This is the once-monthly COVID-19 Evidence Accelerator Diagnostics Lab Meeting. These meetings occur the third Thursday of every month at 12 pm ET. 
Real-World Data Webinar Series: Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for
Real-World Data Webinar Series: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products